Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha1 adrenergic receptor blockers for functional bowel disorders
jRCTs041200057Recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of silodosin and naftopidil in irritable bowel syndrome (IBS), functional constipation (FC), functional diarrhea and 2 more (2 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoints: Overall improvement in IBS symptoms and Improvement in bowel movement in FBD group. Started Nov 2020; status: recruiting.
02
Drugs
silodosinnaftopidil
03
Conditions
irritable bowel syndrome (IBS)functional constipation (FC)functional diarrheaFunctional abdominal distension (FAD)functional bowel disorder (FBD)
Beyond the preview
Go deeper on jRCTs041200057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200057.